Publications by authors named "Yanying You"
Background & Aims: Approved drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) are limited, although it has become the most common chronic liver disease worldwide. 1-phenyl-3-methyl-5-pyrazolone (PMP) possesses various biological effects such as anti-inflammatory and antioxidant. However, the effects and underlying mechanism of PMP in MASH remain unclear.
View Article and Find Full Text PDFArticle Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is linked to metabolic syndrome, which increases cancer risk, prompting the need for customized cancer screening in high-risk patients.
- The study analyzed data from the Global Burden of Disease 2019 to find that metabolic risks significantly contribute to certain cancers, with age-standardized rates showing higher impacts in older men and individuals with a higher socio-demographic index.
- Results suggest a strong connection between NAFLD and various cancers, advocating for focused cancer screenings for those affected by NAFLD, especially those at greater risk.